JMD Conference & Exhibition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bosler, D.
Right arrow Articles by Crisan, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bosler, D.
Right arrow Articles by Crisan, D.
JMD 2006, Vol. 8, No. 4
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology


Review Articles

Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype

A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

David Bosler, Joan Mattson and Domnita Crisan

From the Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, Michigan

Abstract

Venous thromboembolic events (VTEs) affect an estimated 1 in 1000 people annually, resulting in ~50,000 deaths, with prevalence increasing with age. The genetic contributors to thrombosis have been described and further explored within the last 15 years as molecular diagnostic techniques have become more widely used. The prothrombin G20210A mutation is the second most common inherited thrombotic risk factor after factor V Leiden. Generally present in less than 5% of the population, the mutation’s prevalence varies greatly with ethnicity. The G20210A mutation confers a mildly increased thrombotic risk that is compounded by the presence of other risk factors. One striking characteristic of the G20210A mutation is the phenotypic heterogeneity of the rare homozygous cases. Forty percent of the reported homozygous cases are asymptomatic. Many of the symptomatic patients have additional risk factors that might compound the thrombotic risk. We present here a review of the literature for the homozygous prothrombin G20210A mutation and describe additional cases that exemplify the heterogeneous nature of this entity.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology and the Association for Molecular Pathology.